NDAORALTABLETPriority Review
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
21
Data completeness
8/8 — Comprehensive
Priority Review
LIVTENCITY (maribavir) by Takeda is cytomegalovirus pul97 kinase inhibitors [moa]. Approved for cytomegalovirus pul97 kinase inhibitor [epc]. First approved in 2021.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIVTENCITY (maribavir) is an oral small-molecule cytomegalovirus (CMV) pUL97 kinase inhibitor approved by the FDA in November 2021. It treats CMV infection by targeting viral protein kinase, preventing viral replication in immunocompromised patients. This represents the first-in-class oral antiviral mechanism for CMV with a novel target.
$37MPart D
Peak17.1 years to LOEProduct is in peak lifecycle phase with modest commercial uptake (1,458 claims in 2023), suggesting stable team size and focus on market penetration in niche immunocompromised populations.
Mechanism of Action
Cytomegalovirus pUL97 Kinase Inhibitors
Pharmacologic Class:
Cytomegalovirus pUL97 Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Started Nov 2025
10 enrolled
Cytomegalovirus (CMV)Kidney DiseaseKidney Failure
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Started Feb 2025
66 enrolled
Cytomegalovirus (CMV)
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
Started Dec 2024
20 enrolled
Cytomegalovirus (CMV)
A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
Started Nov 2024
168 enrolled
Cytomegalovirus (CMV)
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection
Started Oct 2024
265 enrolled
Cytomegalovirus (CMV)
Worked on LIVTENCITY at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.